Consolidated Financial Statements for the Year Ended March 31, 2020
FY2020 (April 1, 2019 - March 31, 2020) [UNAUDITED]Company name:
Stock exchange listings:
Code number:
URL:
Company representative:
Contact:

May 14, 2020
Takara Bio Inc.
Tokyo Stock Exchange (1st section)4974
http://www.takara-bio.co.jp
Koichi Nakao, President
Takuya Kakemi, General Manager of Corporate
Management Division, Executive Officer
Tel. (077) 565-6970
June 23, 2020
June 24, 2020
June 26, 2020

Scheduled date of general shareholders’ meeting:
Scheduled date of starting delivery of dividends:
Scheduled date of annual securities report filing
date:
Supplementary documents of the financial results:
Yes
Financial results information meeting:Yes
Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles andpractices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.
1. Results for the year ended March 31, 2020 (Apr. 1, 2019 – Mar. 31, 2020)(1) Consolidated operating results(Percentages indicate changes from the same period of the previous fiscal year.)Year ended
Mar. 31, 2020

Net sales
Operating profit
Ordinary profit
Net income (loss) attributable to owners ofparent
Net income per share (in yen)
Fully diluted net income per share (in yen)
(Note) Comprehensive income(Reference) Equity in earnings of affiliates(2) Consolidated financial position
Total assets
Net assets
Equity ratio (%)
Net assets per share (in yen)
(Reference) Equity(3) Consolidated cash flow

Cash flow from operating activities
Cash flow from investing activities
Cash flow from financing activities
Cash and cash equivalents, end year

(Millions of yen)
34,565
6,274
6,347
3,819
31.72－
3,216－

(%)
(3.6)
14.8
12.1
4.4

18.9%

Year ended
Mar. 31, 2019(%)

(Millions of yen)
35,841
5,463
5,665
3,657
30.38
－
2,705－

10.9
53.7
46.7
56.6

10.2%

As of Mar. 31, 2020
(Millions of yen)

As of Mar. 31, 2019
(Millions of yen)

75,00966,591
88.7
552.2366,496

71,04064,09590.1
531.5764,009Year ended Mar. 31, 2020
(Millions of yen)

Year ended Mar. 31, 2019
(Millions of yen)

6,339
(212)
(946)
14,462

5,783(5,576)
(541)
9,464

2. Dividends

First quarter end
Second quarter end
Third quarter end
Year end
AnnualTotal dividend (Millions of Yen)
Payout ratio (%)
Dividend on equity (%)

Year ended
Mar. 31, 2019Year ended
Mar. 31, 2020

Annual dividends per share in yen
Year ending
Mar. 31, 2021 (Forecast)

－－－

0.00

0.00

0.00

－－－

7.00
7.00
842
23.0
1.3

8.00
8.00
963
25.2
1.5

8.00
8.00
37.1

3. Forecast for the year ending March 31, 2021 (Apr. 1, 2020 – Mar. 31, 2021)(Percentages indicated changes from the same period of the previous fiscal year.)Six months ending Sep. 30, 2020
Net sales
Operating profit
Ordinary profit
Net income attributable toowners of the parent
Net income per share (inyen)※(Millions of yen)
14,365
619
693
－(%)

Year ending Mar. 31, 2021

(12.7)(79.6)(76.6)(100.0)0.00

33,800
4,500
4,600
2,600

(2.2)
(28.3)(27.5)(31.9)

21.59

Others(1) Changes in subsidiaries during the period(Changes in specified subsidiaries resulting in change of scope) ： No
Newly included: － (Name)
Excluded: － (Name)(2) Changes in accounting policies, changes in accounting estimates, and retrospective restatement
1) Changes based on revisions of accounting standard： Yes
2) Changes other than ones based on revisions of accounting standard： No
3) Changes in accounting estimates： No4) Restatement： No(3) Number of outstanding shares (Common stock)1) Number of outstanding shares at year end (Treasury stocks are included)
120,415,600
As of March 31, 2020
As of March 31, 2019
120,415,600
2) Number of treasury stocks at year end－As of March 31, 2020－
As of March 31, 20193) Average number of outstanding shares
120,415,600
As of March 31, 2020
120,415,600
As of March 31, 2019

※ These financial statements are not subject to auditing.
※ Comment regarding appropriate use of earnings forecasts and other special notes
Forward-looking statements contained in this document are determined by the Takara Bio Company based on
information currently available to the Company and include a number of uncertainties. Actual results could differ fromthese forecasts due to changes in conditions that occur in the future. For information regarding the above, please refer to1. Overview of Financial Results (4) Future Outlook on page 3 of the attached document.
The Company will hold a briefing for institutional investors and analysts on May 18, 2020. The material handed out at
this briefing and a review of questions and answers will be posted on our website.